SCHEMBL1779824

SCHEMBL1779824

CCOC(=O)n1nc(NC(=O)c2ccc(N3CCN(C)CC3)cc2NC(=O)c2cnoc2C)c2cc(C(=O)NC(C)(C)c3ccccc3F)sc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 1/20 0.38
CSF1R P07333 1/20 0.38
LYN P07948 1/20 0.38
BRAF P15056 1/20 0.38
FLT3 P36888 3/20 0.38
AURKA O14965 2/20 0.37
ABL1 P00519 1/20 0.37
BCR P11274 1/20 0.37
BTK Q06187 1/20 0.37
LCK P06239 1/20 0.36
KDR P35968 1/20 0.36
MAPK14 Q16539 1/20 0.36
INSR P06213 8/20 0.35
ALK Q9UM73 8/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
GAA P10253 1/20 0.35
MAPK1 P28482 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1780828 0.92 AURKA (0.45) RAF1CSF1RLYNBRAFFLT3
SCHEMBL1778613 0.89 BTK (0.40) CSF1RFLT3AURKAABL1BCR
SCHEMBL1777881 0.89 HSD17B10 (0.35) CSF1RKDM4EMEN1ALDH1A1GAA
SCHEMBL1779011 0.89 IGF1R (0.43) FLT3AURKAABL1BCRBTK
SCHEMBL1777980 0.88 AURKA (0.40) FLT3AURKAABL1BCRBTK
SCHEMBL1778668 0.87 PDE7A (0.41) CSF1RLYNFLT3AURKAABL1
SCHEMBL1779183 0.87 ALK (0.42) FLT3AURKAABL1BCRBTK
SCHEMBL1778870 0.87 CSF1R (0.40) RAF1CSF1RLYNBRAFFLT3
SCHEMBL1780614 0.87 RAF1 (0.42) RAF1CSF1RLYNBRAFFLT3
SCHEMBL1780225 0.85 SIRT6 (0.39) FLT3AURKAABL1BCRBTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904503-B1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-11-06 EP disclosed
US-7943654-B2 1H-thieno[2,3-c]pyrazole compounds useful as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-17 US disclosed
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-06-11 US disclosed
EP-1904503-A1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.r.l. (IT) 2008-04-02 EP disclosed
WO-2007009898-A1 1H-THIENO[2,3-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors CCNH, PDK1, MAP3K5 RAF1 220/4885CSF1R 3241/4885LYN 583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.